



For immediate distribution
Source: DIAGNOS inc.

2012.03.28

DIAGNOS Announces Contract with Aboriginal Medical Supplies a division of Home Health Store Inc

Brossard, Quebec, Canada – March 28, 2012 - DIAGNOS inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), leader in algorithm development, data analysis, and image processing, announces today the signing of an agreement with Aboriginal Medical Supplies a division of Home Health Store Inc, a major medical equipment supplier to hospitals, physicians, pharmacists, nurses and home care workers. AMS will represent Diagnos in the sale of CARA (Computer Assisted Retinal Analysis) to all aboriginal communities in Western and Central Canada.

Aboriginal Medical Supplies is a federally approved PSAB supplier of health care products and services to all federal government departments and agencies concerning Aboriginal communities and businesses.

“The PSAB (Procurement Strategy for Aboriginal Business) is a strategy that was launched by the federal government to increase the number of Aboriginal suppliers bidding for, and winning federal contracts. The PSAB makes it easier for the government, Aboriginal firms, and their partners to do business with each other, for example, certain contracts are being set aside for competition among Aboriginal businesses in partnership with non aboriginal companies that can supply new technologies and services to the aboriginal communities”, Said Whitney Modersohn, president of AMS.

Aboriginal peoples in Canada comprise the First Nations, Inuit and Métis totaling 1,172,790 people, or 3.8% of the national population. “The prevalence of diabetes is staggering: one in three members of our communities has diabetes, and our plan is to introduce the screening program using CARA to all these communities. In all of the conferences that we attend we are continuously being told that retinal screening is an absolute necessity and a key component in indentifying, treating, and educating Aboriginal people in managing their health and saving their vision. CARA’s teleophthalmology platform will allow us to get those that require immediate care to a retinal specialist, and because of CARA’s triage capability, savings in transportation and lodging will be significant”, Said Whitney Modersohn, president of AMS.

About CARA

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real-time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, and the European Union.

About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com. You may also contact our investor relations representative:

André Larente, President
DIAGNOS inc.
Tel.: 1-877-678-8882 or (450) 678-8882, ext.: 224
alarente@diagnos.com

Louis Morin
Bid Capital Markets
Tel.: 514-845-1101
bidcapital@videotron.ca